Literature DB >> 2554951

Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils.

P J Roberts1, D Cummins, A L Bainton, K J Walshe, S P Fisher-Hoch, J B McCormick, J G Gribben, S J Machin, D C Linch.   

Abstract

A recurrent theme in studies of the pathology of fatal Lassa fever in man is the lack of histological lesions to explain disordered cell function and death. Recently, we demonstrated the existence of a factor in the plasma of patients with Lassa fever which markedly inhibits the aggregation responses of normal platelets in vitro. To assess whether this factor could mediate more global cellular dysfunction, we studied the effects of Lassa plasma on the respiratory burst of neutrophils. Thirteen of 15 samples from patients in the acute phase of Lassa fever profoundly inhibited the amount of superoxide generated by normal neutrophils in response to the chemotactic peptide, f-met-leu-phe (FMLP) (mean superoxide generated = 54.7 +/- 6.1% of control). In contrast, eight of nine samples from patients who had infections other than Lassa fever enhanced the neutrophil response to the peptide. All Lassa samples which inhibited the ADP-induced aggregation responses of normal platelets inhibited the neutrophil response to FMLP. Unlike the effect on platelets, however, the inhibition of neutrophils was only apparent when the cells were stimulated within 5 min of exposure to the plasma. The inhibition of neutrophils is not due to either interference with FMLP-neutrophil binding or an effect on the NADPH-oxidase, suggesting a suppression of signal transduction. Our data suggest the inhibitory factor in Lassa plasma has global effects on cellular function, and may play a central role in the pathogenesis of this often fatal illness.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554951     DOI: 10.1111/j.1365-2141.1989.tb00245.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

2.  Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression.

Authors:  I S Lukashevich; R Maryankova; A S Vladyko; N Nashkevich; S Koleda; M Djavani; D Horejsh; N N Voitenok; M S Salvato
Journal:  J Med Virol       Date:  1999-12       Impact factor: 2.327

Review 3.  Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.

Authors:  Juan C Zapata; C David Pauza; Mahmoud M Djavani; Juan D Rodas; Dmitry Moshkoff; Joseph Bryant; Eugene Ateh; Cybele Garcia; Igor S Lukashevich; Maria S Salvato
Journal:  Antiviral Res       Date:  2011-07-27       Impact factor: 5.970

4.  Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains.

Authors:  César G Albariño; Brian H Bird; Ayan K Chakrabarti; Kimberly A Dodd; David M White; Eric Bergeron; Punya Shrivastava-Ranjan; Stuart T Nichol
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

5.  Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus.

Authors:  Igor S Lukashevich; Mahmoud Djavani; Juan D Rodas; Juan C Zapata; Amy Usborne; Carol Emerson; Jacque Mitchen; Peter B Jahrling; Maria S Salvato
Journal:  J Med Virol       Date:  2002-06       Impact factor: 2.327

6.  Exchange transfusion of a patient with fulminant Lassa fever.

Authors:  D Cummins; D Bennett; S J Machin
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 7.  Review: Viral infections and mechanisms of thrombosis and bleeding.

Authors:  M Goeijenbier; M van Wissen; C van de Weg; E Jong; V E A Gerdes; J C M Meijers; D P M Brandjes; E C M van Gorp
Journal:  J Med Virol       Date:  2012-10       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.